eac difference

success stories

Value Assessment to Determine Business Relationships +

EAC’s analytical expertise gives us the capacity to create powerful and important tools for value assessment. When a recent client was on the market to be acquired, EAC was able to calculate the value of its specific companion diagnostic toolkit, both in terms of the millions of dollars it was worth to the entire health care system, and also in terms of the value it added to the company. As a result, the client was acquired for a favorable price, because EAC could incorporate the value of the companion diagnostics into the total value of the company.

Technology Assessment Guides Optimal Platform Development

EAC’s background in pharma and diagnostics, coupled with our outstanding research and business-analysis capacities, puts us a in perfect position to assess new medical technology. A client in biotech manufacturing recently developed a hand-held testing device that could provide immediate results from a blood draw and store associated data for analysis, as well. The potential benefits of the device were huge, but due to the production costs, the commercially viability was uncertain. EAC determined that the high cost of a chip in the device was unlikely to fall quickly, and the client had unrealistically optimistic cost curve projections. EAC’s business model expertise allowed us to devise a different market plan for the product that ensured the client long-term profits.

Major Research Study Identifies Economic Benefits of POC Device Connectivity +

EAC has long been on the cutting edge of developments in medical technology, and studies done by EAC were instrumental in leading the sea change to device connectivity. Only a few years ago, handheld POC instruments lacked the ability to communicate with hospital and lab based computer systems. Users gathered data in a POC device and then manually entered it into a computer, sometimes multiple times. A manufacturer of glucose meters considered developing a model with connectivity, if it could be shown that there was sufficient economic value. EAC stepped in with a 3-phase study and analysis.

The first phase, involving in-depth interviews and observations, identified ways that lack of connectivity was hurtful both medically and commercially. The second phase duplicated these findings in a dozen institutions, and the third phase, a broad survey of 100 institutions, confirmed the magnitude of the problem. EAC’s mathematical model showed potential savings of at least $100,000 and up to $1,000,000 per institution if connectivity were adopted. The manufacturer, convinced the product would be marketable, went forward and invested in connectivity, at the beginning of what became a hot new trend and ultimately the standard for POC devices.

EAC Study of Next-Gen Genomics Technology Determines Growth Strategies Path +

When a leading biotechnology firm considered expanding into bioinformatics, they needed crucial information about the industry, and a business model that would succeed. EAC’s in-house domain knowledge, ties to key industry opinion leaders, and talent in primary research make us leaders in answering just such questions. Our research in next-gen genomics technology identified the current status of bioinformatics software and infrastructure, the difficulties faced by the industry, and the areas in the center of bioinformatics innovation. Our experts interpreted the data and developed possible business plans. With these tools, our client was able to decide on emphases in future bio-informatics software development, marketing strategies, and technical collaborations and partnerships.